Cartalax 20mg*10vials

Cartalax (Ala‑Glu‑Asp; “AED”) is described in the scholarly literature as an ultrashort, cartilage‑associated peptide motif that can influence fibroblast activity and extracellular‑matrix regulation in vitro.Ultrashort peptides are known to utilize peptide transporters (e.g., POT/LAT families) and demonstrate cell‑penetrating and gene‑expression effects in model systems

• Reconstitute: Add 3.0 mL bacteriostatic water per 20 mg vial → ~6.67 mg/mL concentration.
• Example daily range (measurement framework): 2,000–5,000 mcg once daily (gradual titration for syringe readability; see volume tolerability notes).
• Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
• Handling: Use aseptic technique and follow recognized subcutaneous administration guidance (angle, site, no aspiration)

• Week	Daily Dose (mcg)	Units (per injection) (mL)
  Weeks 1–2	2,000 mcg (2.00 mg)	30 units (0.30 mL)
  Weeks 3–4	3,000 mcg (3.00 mg)	45 units (0.45 mL)
  Weeks 5–6	4,000 mcg (4.00 mg)	60 units (0.60 mL)
  Weeks 7–12	5,000 mcg (5.00 mg)	75 units (0.75 mL)

  Reconstitution Steps

  1. Using aseptic technique, draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Insert the needle through the stopper and let the diluent run slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until fully dissolved (do not shake). Maintain sterility per best‑practice guidance.
  4. Label the vial and handle with standard precautions; avoid repeated freeze–thaw and protect from light exposure when practical.
  Evidence note: Published human posology specific to Cartalax (AED) is limited; the once‑daily SC framework above prioritizes measurement clarity and SC tolerability while aligning with recognized SC technique and volume considerations from authoritative sources.